Comparison between kinetic modelling and graphical analysis for the quantification of $^{[18F]}$fluoromethylcholine uptake in mice

Dominique Slaets* and Filip De Vos

Abstract

Background: Until now, no kinetic model was described for the oncologic tracer $^{[18F]}$fluoromethylcholine ($^{[18F]}$FCho), so it was aimed to validate a proper model, which is easy to implement and allows tracer quantification in tissues.

Methods: Based on the metabolic profile, two types of compartmental models were evaluated. One is a 3C2i model, which contains three tissue compartments and two input functions and corrects for possible $^{[18F]}$fluorobetaine ($^{[18F]}$FBet) uptake by the tissues. On the other hand, a two-tissue-compartment model (2C1i) was evaluated. Moreover, a comparison, based on intra-observer variability, was made between kinetic modelling and graphical analysis.

Results: Determination of the $^{[18F]}$FCho-to-$^{[18F]}$FBet uptake ratios in tissues and evaluation of the fitting of both kinetic models indicated that corrections for $^{[18F]}$FBet uptake are not mandatory. In addition, $^{[18F]}$FCho uptake is well described by the 2C1i model and by graphical analysis by means of the Patlak plot.

Conclusions: The Patlak plot is a reliable, precise, and robust method to quantify $^{[18F]}$FCho uptake independent of scan time or plasma clearance. In addition, it is easily implemented, even under non-equilibrium conditions and without creating additional errors.

Keywords: PET; $^{[18F]}$Fluoromethylcholine; Kinetic modelling; Patlak plot; Graphical analysis; Metabolic trapping
of compartmental models were evaluated (Figure 1): a 3C2i model which contains three tissue compartments and two input functions (one for $[^{18}\text{F}]\text{FCho}$ and one for $[^{18}\text{F}]\text{FBet}$) and corrects for possible $[^{18}\text{F}]\text{FBet}$ uptake by the tissues, and a 2C1i model which contains two tissue compartments and one input function and quantifies the $[^{18}\text{F}]\text{FCho}$ uptake, based exclusively on $[^{18}\text{F}]\text{FCho}$ plasma concentrations. As kinetic modelling, using non-linear least squares optimisation, is computationally expensive and sensitive to noise, a comparison will be made between kinetic modelling and graphical analysis to quantify $[^{18}\text{F}]\text{FCho}$ uptake in tissues. The latter uses a linearization of the compartmental equations, resulting in a faster method which is less sensitive to noise [7].

Methods

Athymic Swiss Nu/Nu mice (female, 20 g) were obtained from Charles River Laboratories International (Janvier, France). Sulphuric acid, urea, dimethylaminoethanol, chloroform, and methanol were purchased from Sigma-Aldrich (Steinheim, Germany). Physiological saline was obtained from B.Braun Medical Ltd. (Sheffield, UK). Isoflurane and heparin were obtained from Medini N.V. (Oostkamp, Belgium).

Radiochemistry

$[^{18}\text{F}]\text{FCho}$ was prepared by nucleophilic substitution of dimethylaminoethanol to $[^{18}\text{F}]\text{fluoromethylbromide}$ as described by Slaets et al. [8].

**Figure 1** Visual representation of the different kinetic models. (a) Schematic of a two-tissue-compartment model with one input function (2C1i). Transfer coefficients $K_1$ and $k_2$ describe the uptake and washout of the free tracer and its metabolite ($[^{18}\text{F}]\text{FBet}$) across cell membranes. Rate constant $k_3$ is regarded as the conversion of $[^{18}\text{F}]\text{FCho}$ into $[^{18}\text{F}]\text{FPCho}$, which is assumed to be metabolically trapped in the cell. Micro-parameter $k_4$ represents dephosphorylation and is expected to be very small. (b) Schematic of a three-tissue-compartment model with two input functions (3C2i). Rate constants $K_{10}$ and $K_{11}$, or $k_{20}$ and $k_{2m}$ represent respectively the uptake and washout of $[^{18}\text{F}]\text{FCho}$ and $[^{18}\text{F}]\text{FBet}$.

**Positron emission tomography**

All animal experiments were approved by the local ethics committee (ECD 11/30). Mice ($n = 6$) were harvested 8 h prior to the study and anaesthetized with isoflurane (1.5% + 1.5 L/min O$_2$) during cannulation, animal handling, and acquisition time. Prior to positioning on the heated scanner bed, the mice were venously and arterially cannulated for tracer injection and arterial blood sampling, respectively. Positron emission tomography (PET) was performed using a Flex Triumph II μPET scan (Gamma Medica, Sherbrooke, Quebec, Canada) with a 7.5-cm axial field of view and a 1.2-mm spatial resolution. After the synchronized start of the arterial blood sampling and the start of the μPET acquisition, the tracer was intravenously injected (±11.1 MBq in 150 μL saline) over a constant infusion interval of 5 s. List mode data were acquired for 40 min.

**Arterial input function determination**

**Blood concentration**

Continuous arterial blood samples were withdrawn for 40 min at a rate of 10 μL/min using a microvolumetric blood counter (μBC, Gamma Medica-Ideas) as described by Convert et al. [9]. Heretofore, a 60-cm PE10 catheter filled with heparinized saline (50 U/mL) was inserted in the carotid artery and the withdrawing syringe was placed at the end. At a distance of 20 cm from the mouse, the catheter was placed in the calibrated detector unit of the μBC. The obtained blood curve ($g(t)$) was automatically corrected for decay and propagation delay. Corrections for dispersion were performed using Equation 1:

$$C_{bd}(t) = g(t) + r_{disp} \times \frac{dg}{dt} \quad (1)$$

In Equation 1, $g(t)$ depicts the original blood curve, $\frac{dg}{dt}$ describes the first derivative of the original blood curve, $r_{disp}$ is a constant calculated as described by [9], and $C_{bd}$ represents the for dispersion-corrected blood curve.

**Plasma concentration and metabolites**

The ratio of the tracer plasma to blood concentration and metabolite profile was determined ex vivo in Swiss Nu/Nu mice ($n = 4$ per time point) by an intravenous injection of 22.2 MBq $[^{18}\text{F}]\text{FCho}$ in 150 μL saline. Blood (200 μL) obtained by cardiac puncture in the left heart ventricle at 0.5, 2.5, 10, 20, and 40 min post injection was collected in heparinized tubes and spiked with 5% sulphuric acid (100 μL) and a 40% urea solution (100 μL) before centrifugation (5 min, 3,000xg). Plasma and the hematocrit pellet were separated and assessed for radioactivity. Then, 600 μL of the Bligh and Dyer extraction solution containing CHCl$_3$:MeOH:H$_2$O (1:2:1)
was added to the supernatant (200 μL) of all time points except that of 0.5 min (post injection) p.i. and mixed vigorously before centrifugation (5 min, 3,000×g). Finally, the two layers were separated and assessed for radioactivity, and 500 μL of the aqueous layer was injected to a semi-preparative high-performance liquid chromatography (HPLC) system for aqueous metabolite analysis as described by Bansal et al. [10]. The HPLC system consisted of a Waters 1525 binary pump (Waters, Milford, MA, USA), a Waters Breeze data acquisition, and an Alltima silica NP column (5 μm, 10 × 250 mm). The following gradient elution [10] was used at a rate of 7 mL/min. The retention time of [18F]FCho was determined by extraction (vide supra) of the reference solution and was 14.4 min. The metabolite [18F]FBet had a retention time of 12.4 min in the chromatographic separation. During separation, fractions of 20 s were collected and assessed for radioactivity. The tracer plasma-to-blood concentration ratio was calculated as (Equation 2)

\[
\frac{C_{\text{pl}}}{C_{\text{bl}}} = \frac{\text{CPS}_{\text{pl}}}{\text{CPS}_{\text{bl}}} = \frac{\text{CP}^{\text{bl}}}{\text{CP}^{\text{pl}}}
\]  

In Equation 2, the ratio of the plasma to blood concentration is calculated for several time points (vide supra). The plasma concentration (C\text{pl}) was determined by dividing the counts in the plasma (CPS\text{pl}) to the standardized volume of plasma in blood (%pl, which is expressed as 0.6). In analogy, the tracer blood concentration (C\text{bl}) was calculated by taking the ratio of the sum of the counts in the plasma and hematocrit pellet (represented by CPS\text{bl}) to the blood volume, which is expressed as 1.

The obtained ratios and metabolite percentages were fitted to a single-phase exponential curve. The goodness of the fit and the equation were calculated using GraphPad Prism 5.00 for Windows (San Diego, CA, USA; www.graphpad.com).

**Image reconstruction and corrections**

Dynamic images were reconstructed using the MLEM 2D algorithm with ten iterations to the following time frames: 12 s × 5 s, 6 s × 10 s, 6 s × 20 s, 6 s × 60 s, 4 s × 120 s, 3 s × 300 s, and 1 s × 360 s. Quantification of the PET scan was performed relative to a 22Na source placed on the base of the scanning bed.

**Regional time-activity curve computation**

The last time frame was used to draw a region of interest on two to three adjacent slices on a part of the tissue of interest, namely the brain, kidney, lung, liver, and muscle. The ROIs were then placed over the complete series of time frames to derive tissue time-activity curves.

**Kinetic modelling**

The exploit of kinetic modelling to [18F]FCho is based on the following general assumptions [11,12]:

There is a single source for [18F]FCho, i.e. the plasma. The concentration varies with time, and transfer from the plasma to the first tissue compartment is reversible. The capillary concentration of [18F]FCho is assumed to be equal to the arterial plasma concentration, so no gradient could be observed across the capillary membranes. Since tracer amounts were injected (high specific activity), the test solute did not alter the system and first-order kinetics could be assumed. [18F]FCho is homogeneously distributed in the tissues. Metabolism of choline is under steady state, so the concentration of phosphocholine stays constant during imaging.

In addition to the previous assumptions, [18F]FCho is metabolized to (1) [18F]fluorophosphocholine which is suspected to be metabolically trapped and (2) [18F]FBet, an osmolyte, which is able to cross the cell membranes.

Kinetic analysis was performed using a 3C2i as described by Fujita et al. [13] and was weighed against a 2C1i (Figure 1). The models are described by following the micro-parameters: K1, k2, k3, and k4 for the 2C1i model; and the additional parameter \(\frac{K_{1p}}{K_{1m}}\) which represents the ratio of [18F]FCho to [18F]FBet uptake in tissues in the 3C2i model. Transfer coefficients K1 and k2 describe the uptake and washout of the free tracer and its metabolite ([18F]FBet) across cell membranes. Rate constant k3 is regarded as the conversion of [18F]FCho into [18F]FPCho, which is assumed to be metabolically trapped in the cell. Micro-parameter k4 represents dephosphorylation and is expected to be very small. The 3C2i model differentiates between [18F]FCho and [18F]FBet uptake or washout by rate constants K1p and K1m, or k2p and k2m, respectively. During the fitting process using the 3C2i model, six parameters were identified. The vascular volume parameter, present in both models, was not accounted for due to the fast clearance of [18F]FCho. Parameters of interest were the ratio of [18F]FCho to [18F]FBet uptake in tissues, represented by \(\frac{K_{1p}}{K_{1m}}\) for the 3C2i model, and the [18F]FCho influx across the membranes (K_i) calculated as \(K_i = k_3/(k_1 + k_2)\) [14-16] for both models.

Before the selected kinetic models were fitted, the tracer plasma curves were fitted using a three-exponential decay function [17]. Then, model fitting was conducted and optimized by (1) visual inspection of the...
agreement of time-activity curve (TAC) and the model output, (2) evaluation of the percent coefficient of variation of the micro-parameters, and (3) the goodness of fit displayed by the Akaike information criterion (AIC), Schwartz criterion (SC), and model selection criterion (MSC) as determined by the PMOD software (PMOD version 3.0; PMOD group, Zurich, Switzerland). When the fitting was poor, fits were redone by adjusting the initial parameters. Parameter estimation, in kinetic modelling, was performed using the Marquardt-Levenberg algorithm, which uses a non-linear least squares optimization process, included in the PMOD software.

**Graphical analysis**
Since absolute quantification of $^{[11C]}$Cho was already established by means of the Patlak plot [12,17], this graphical analysis was also applied for $^{[18F]}$FCho. The macro-parameter of interest, i.e. the slope, which resembles $^{[18F]}$FCho influx into the cells, was determined under non-equilibrium and equilibrium conditions. The latter is usually achieved when the graphical plot describing normalized tissue concentration as a function of the normalized time becomes linear [11,12]. It is worth noting that the Patlak slope corresponds to the macro-parameter of interest $K_i$, defined previously during the kinetic modelling process.

**Intra-observer variability of macro-parameters**
A test was performed to evaluate the robustness of the macro-parameter estimation of the $^{[18F]}$FCho influx (i.e. $K_i$) (vide supra) using these three models, i.e. 3C2i, 2C1i, and the Patlak plot. The percent error is calculated as (Cho influx test − Cho influx retest)/(mean test and retest).

**Statistical analysis**
Statistical analysis was performed using Graphpad Prism 5.00. A D’Agostino-Pearson test was conducted to test for normality distribution of the data. Since samples were too little, non-parametric statistical tests were used. A Bland-Altman plot was determined to evaluate the percent error during the intra-observer variability test. A Kruskal-Wallis test was performed to evaluate statistical differences between (1) the AIC, SC, and MSC fitting factors of the different models evaluated and (2) the determined $^{[18F]}$FCho influxes across the cell membrane by comparing the macro-parameter $K_i$. A Wilcoxon signed-rank test was applied to evaluate if the median ratio $K_{1p}/K_{1m}$, which represents the ratio of $^{[18F]}$FCho to $^{[18F]}$FBet uptake in tissues in the 3C2i model, was statistically different from 1. A Spearman correlation test was performed to evaluate the influence of equilibrium conditions on the model’s Patlak slope. Differences were regarded as statistically significant for $p < 0.05$.

**Results**

**Arterial input function determination**
Since kinetic modelling requires an arterial plasma input function of the unmetabolized tracer, corrections are forced on the blood curve which was obtained by the microvolumetric blood counter. The corrections applied were dispersion correction, conversion of the blood curve into a plasma curve, and corrections for metabolites.

**Dispersion**
Based on the specification of tubing diameter (PE 10), withdrawal speed (10 μL/min), and distance to the detector unit (i.e. 20 cm), the $\tau_{\text{disp}}$ constant was calculated as 12.2092 s. All blood curves were first smoothed by calculating the average concentrations (kBq/cm$^3$) in agreement with the μPET mid-time frames and then corrected for dispersion as described by Equation 1. An original blood curve and its corresponding dispersion-corrected blood curve are displayed in Figure 2a.

**Plasma concentration**
The ratio of the plasma to blood concentration was fitted by a single-phase exponential decay (Figure 2b) with

![Figure 2](http://www.ejnmmires.com/content/3/1/66)
\( R^2 = 0.9374 \) and a corresponding equation (Equation 3):

\[
\frac{C_{pl}}{C_{bl}} = 0.6007 \times e^{-0.4559 \times \text{time (min)}} + 1.116. \tag{3}
\]

The plasma concentration was achieved by multiplying the obtained ratios for each time point by the dispersion-corrected blood curve as determined previously.

**Corrections for metabolites and parent compound**

Use of the Bligh and Dyer extraction mixture allowed estimation of the percentage of lipophilic metabolites, while the HPLC analysis of the hydrophilic fraction allowed identification and quantification of the amount of hydrophilic metabolites and parent compound in the plasma. The fraction of lipophilic compounds in the plasma was lower than 5% for all time points (Table 1); therefore, no further corrections were made to correct for the share of these metabolites. On the other hand, only one hydrophilic metabolite, i.e. \([^{18}F]FBet\), which appeared rather quickly, was identified in the plasma (Figure 2c). Indeed, after 10 min \([^{18}F]FBet\) already amounts to 58.54%. The measured percentages of \([^{18}F]FCho\) and \([^{18}F]FBet\) were fitted to a single-phase exponential curve respectively with Equations 4 and 5 and \( R^2 = 0.9435 \).

\[
\%[^{18}F]FCho = 0.8043 \times e^{-0.1497 \times \text{time (min)}} + 0.2346
\tag{4}
\]

\[
\%[^{18}F]FBet = 0.8043 \times e^{-0.1498 \times \text{time (min)}} + 0.7653
\tag{5}
\]

The corresponding percentages per time point obtained from Equations 4 and 5 were multiplied by the plasma curves (vide supra) to obtain the input functions for the selected compartmental models, i.e. the 2Ci and 3Ci models. The \([^{18}F]FCho\) plasma concentration was the only input function in the 2Ci model, whereas the \([^{18}F]FCho\) plasma concentration and the \([^{18}F]FBet\) plasma concentrations were both used in the 3Ci model.

**Kinetic modelling**

Prior to the mathematical modelling, the obtained input function was fitted to a three-exponential function.

When the 3Ci and 2Ci models were fitted to the TACs, the goodness of fit was described by AIC, SC, and MSC parameters presented in Table 2. Comparing these parameters, no statistical differences were observed between the 3Ci and the 2Ci model (p values for the Kruskal-Wallis test were 0.9925, 0.8276, and 0.9342, respectively), albeit reducing the number of compartments accordingly decreased the percent coefficient of variance (%COV) on the micro-parameter estimates (data not shown).

For each tissue, the mean ratio of \([^{18}F]FCho\) to \([^{18}F]FBet\) uptake in tissues (\(K_{1p}/K_{1m}\)) was larger than 1 (Figure 3). However, only the ratio of the muscle tissue was statistically different from 1 (Wilcoxon signed-rank test, \( p = 0.0313 \)). Kidney tissue displayed the lowest ratio, indicating an elevated (or slightly higher) \([^{18}F]FBet\) uptake compared to the other tissues. It is worth noting that ratios with a %COV higher than 250% were treated as unreliable and were excluded from the dataset. When comparing the estimates of the \([^{18}F]FCho\) influxes across the cell membrane with or without corrections for possible \([^{18}F]FBet\) uptake (3Ci versus 2Ci model), no significant differences were observed for both models (Kruskal-Wallis test, \( p = 0.8670 \)) (Figure 4).

**Graphical analysis**

Equilibrium conditions of the tracer were determined and were usually achieved between 1 and 23 min after injection. Then, linear regression was applied to the data with a good fit (Chi square, 0.0054505 ± 0.0049021) allowing estimation of the slope, which resembles the \([^{18}F]FCho\) influx into the cell. When comparing the Cho influxes \(K_i\) calculated for the 2Ci and 3Ci model with the slope of the Patlak plot, a good agreement was achieved and no statistical differences were observed (Kruskal-Wallis test, \( p = 0.8270 \)) (Figure 4).

**Intra-observer variability of macro-parameters**

To evaluate the robustness of the fitting of previously described models, the intra-observer variability was determined and depicted in a Bland-Altman plot (Figure 5). This plot corroborates that reduction of the number of compartments drastically reduces the percent error on the intra-observer variability. Consequently, the lowest intra-observer variability was obtained when graphical analysis, by means of the Patlak plot, was applied. It must be noted that the Patlak plot gave 0% error in several cases, while the other models (3Ci and 2Ci) almost never did.

Since a robust fitting was obtained for the Patlak plot, it was investigated whether the tracer influx, determined by the slope of the linear regression, varied under equilibrium and non-equilibrium conditions. Several fittings
indicated a good correlation between equilibrium and non-equilibrium conditions for all tissues, except the kidneys (Figure 6), thereby proving the insensitivity of the slope fitting in relation to the manual selection of the data points. Indeed, equilibrium conditions were selected by visual inspection and by including or excluding data time points to obtain a linear fit. Non-equilibrium conditions were obtained by including all data points in the linear regression (Figure 7).

**Discussion**

Kinetic modelling requires arterial sampling which can be obtained by taking continuous or discrete blood samples. The latter is laborious, requires more animals due to the limited blood volume, and is characterized by complicated sampling intervals within a specific time window. Therefore, we chose to use the validated microvolumetric blood counter [9] to obtain continuous arterial blood samples by cannulation of the carotid artery by a precision operation and a syringe pump. The obtained blood curve was first smoothed in order to derive the first derivative, and then the dispersion constant was applied for dispersion correction, which occurred in the tubing during blood sampling.

Since only unbound tracer in plasma undergoes tissue uptake, a ratio of the plasma to blood concentration \((C_{pl}/C_{bl})\) was determined to convert the blood curve into a plasma curve. Therefore, standard hematocrit ranges [18] were used since the exact hematocrit and plasma volumes could not be determined after the addition of urea and sulphuric acid. Then, the discrete ratios were plotted and obtained a good fit using a one-exponential curve. It was preferred to use the equation obtained for blood-to-plasma corrections rather than a constant value, which would consequently underestimate plasma concentrations at early time points with perturbation of tracer uptake or unidirectional influx rate value (i.e. \(K_1\)) as a result. In addition, the distribution of the plasma-to-blood concentration ratio indicates that \([18F]FCho\), as \([11C]Cho\) [19], is accumulated into the red blood cells.

Comparing the blood metabolism of \([18F]FCho\) to \([11C]Cho\) [19], the following accordances were observed: (1) plasma extraction with chloroform proved that the amount of lipophilic \([18F]FCho\) metabolites in the plasma (<5%, Table 1) is negligible, and (2) \([18F]FBet\) was the only metabolite present in the plasma and it appeared almost immediately. Indeed, at 5 and 25 min post injection, 67.47% and 33.43% \([18F]FCho\) could be detected, which correspond respectively to 62% and 18% \([11C]Cho\) in the plasma [19] and to the metabolism pattern as described by Bansal et al. [10]. Therefore, we can conclude that fitting the percentage of the parent compound in the plasma to a one-exponential curve [20] provides a good fit \((R^2 = 0.9435)\). When using a three-exponential function as described by Roivainen

### Table 2 Fitting factors per tissue (AIC, SC, and MSC) for 3C2i and 2C1i models

| Tissue     | 3C2i          | 2C1i          | 3C2i          | 2C1i          | 3C2i          | 2C1i          |
|------------|---------------|---------------|---------------|---------------|---------------|---------------|
| Brain      | 90.54 ± 31.56 | 91.44 ± 21.48 | 98.72 ± 31.63 | 97.00 ± 21.68 | 1.36 ± 0.52   | 1.341 ± 0.425 |
| Kidney     | 24.63 ± 34.18 | 19.40 ± 30.54 | 32.81 ± 34.23 | 25.19 ± 30.58 | 3.188 ± 0.634 | 3.292 ± 0.554 |
| Liver      | 51.97 ± 50.19 | 61.03 ± 41.54 | 60.13 ± 50.16 | 66.68 ± 41.43 | 2.708 ± 1.308 | 2.544 ± 1.099 |
| Lung       | 44.92 ± 24.72 | 47.79 ± 19.50 | 53.11 ± 24.75 | 49.06 ± 27.39 | 2.669 ± 0.616 | 2.600 ± 0.490 |
| Muscle     | 92.96 ± 15.28 | 90.34 ± 15.73 | 100.5 ± 15.85 | 95.90 ± 15.93 | 1.489 ± 0.431 | 1.549 ± 0.333 |

**Figure 3** Visual representation of the \([18F]FCho\)-to-\([18F]FBet\) uptake ratio in several tissues. The \([18F]FCho\)-to-\([18F]FBet\) uptake ratio represented by \(K_{P}/K_{m}\) was determined by the 3C2i model. The individual data points are shown, and the whiskers represent mean and S.D. The dotted line represents a ratio equal to 1.

**Figure 4** Representation of the \([18F]FCho\) influx determined by the different kinetic models. The tracer influx \((K)\) was calculated as \(K_1* (k_2 + k_3)\) for the different tissues.
et al. [19], fittings were not altered nor improved. Therefore, the one-exponential function was applied for metabolite corrections.

In general, kinetic models are developed as comprehensible models, which accurately describe the metabolic process or receptor binding, but are usually simplified to yield workable models that are able to quantify a parameter of interest. In oncology, this parameter is usually a specific enzyme or transporter, which can be described by a micro-parameter of the selected model. However, in a number of cases, the metabolic rate, which is a combination of micro-parameters, is determined, for example, glucose metabolic rate by $[^{18}\text{F}]$FDG [21] or cell proliferation rate by $[^{18}\text{F}]$FLT [15]. When evaluating the 3C2i model, the $[^{18}\text{F}]$FCho influx across the cell membranes was calculated with corrections for (possible) $[^{18}\text{F}]$FBet uptake, and the ratio of $[^{18}\text{F}]$FCho to $[^{18}\text{F}]$FBet uptake in tissues ($K_{1p}/K_{1m}$) was determined. The latter designates the magnitude of $[^{18}\text{F}]$FBet uptake in the tissues and indirectly shows if additional corrections for $[^{18}\text{F}]$FBet uptake should be implemented. These experiments showed that despite the explicit metabolic pattern, $[^{18}\text{F}]$FBet uptake in the tissues is still limited, and so adjustments for its uptake should not be accounted for during kinetic modelling. Indeed, the $[^{18}\text{F}]$FCho influx determined by the 3C2i model (which corrects for $[^{18}\text{F}]$FBet uptake) and the sum of the $[^{18}\text{F}]$FCho and $[^{18}\text{F}]$FBet influx as determined by the 2C1i model were regarded as not statistically different (Figure 4). Furthermore, when comparing goodness-of-fit factors (i.e. AIC, SC, and MSC), no statistical enhancement (or superior fitting) could be detected by one of the models (i.e. 2C1i and 3C2i). It is worth noting that reducing the number of compartments, or in this case the input functions, consequently decreased the %COV of the micro-parameter estimates, resulting in reduced uncertainties. This was also observed in the intra-observer variability test. Therefore, we can conclude that the 2C1i is a workable kinetic model to estimate the $[^{18}\text{F}]$FCho influx without creating additional errors.

Since $[^{18}\text{F}]$FCho is a tracer which is assumed to be metabolically trapped in cells, including tumour cells [22], graphical analysis was applied to quantify the $[^{18}\text{F}]$FCho influx across cell membranes. We evaluated if selection of the equilibrium time frame had an influence on the slope of the Patlak model, which is a measure of the $[^{18}\text{F}]$FCho influx constant (i.e. $K_i$). The Spearman correlation plot showed a good agreement for all tissues, except for kidney tissue. This might be due to the fact that the kidneys are responsible for tracer elimination, which affects the tracer accumulation and therefore might influence the fitting of the model. Since other tissues provided good correlations, we might conclude
that non-equilibrium conditions do not influence the linear fitting for this radiotracer. These findings corroborate the Spearman correlation test which demonstrates the insensitivity of the \([^{18}\text{F}]\text{FCho}\) influx constant (i.e. \(K_i\)) toward the selection of the linear portion. The fitting can thus be performed without selection of the equilibrium conditions which considerably simplifies the modelling process. Hence, graphical analysis, by means of the Patlak plot, is a very suitable way to estimate \([^{18}\text{F}]\text{FCho}\) influx across the cell membranes, except for kidney tissues. It is worth noting that the influx constant depends on imaging time, the type of tissue, and the type of tracer used, so preceding validation studies should be performed prior to implementation of the non-equilibrium data to the fitting process.

When comparing the \([^{18}\text{F}]\text{FCho}\) influx calculated by the 2C11 model (\(K_i\)) with the Patlak slope, no statistical differences were observed (Kruskal-Wallis test), indicating a good agreement between both methods. On the other hand, the intra-observer variability test (Figure 5) favours the Patlak model, seeing that this analysis obtained the smallest percent error. The latter corresponds to the highest robust method for absolute quantification.

**Conclusions**

Despite the early presence of the metabolite \([^{18}\text{F}]\text{FBet}\) in the blood, no explicit metabolite uptake was observed in the tissues. Consequently, modelling of the \([^{18}\text{F}]\text{FBet}\) uptake should not be performed during quantification of \([^{18}\text{F}]\text{FCho}\) uptake in tissues. \([^{18}\text{F}]\text{FCho}\) uptake is well described by the 2C11 and the Patlak model. Our preference goes to the latter since it is a reliable, precise, and robust method independent of scan time or plasma clearance. In addition, the Patlak plot could easily be implemented, even under non-equilibrium conditions and without creating additional errors, for the quantification of \([^{18}\text{F}]\text{FCho}\) uptake as, for example, in a therapy response assessment.

**Abbreviations**

\([^{18}\text{F}]\text{FCho}\): \([^{18}\text{F}]\)fluoromethylcholine; \([^{18}\text{F}]\text{FBet}\): \([^{18}\text{F}]\)fluorobetaine; AIC: Akaike information criterion; MSC: Model selection criterion; SC: Schwartz criterion; SUV: Standardized uptake values.

**Competing interests**

Both authors declare that they have no competing interests.

**Authors’ contributions**

DS carried out the study concept and design, analyzed and interpreted the data, and wrote the manuscript. FDV coordinated and revised the manuscript. Both authors read and approved the final manuscript.
Acknowledgments

The authors wish to thank the Infinity small animal imaging lab and Prof. C. Vanhove for the registration and reconstruction of the μPET scans.

Received: 29 May 2013 Accepted: 8 September 2013
Published: 14 September 2013

References

1. Mertens K, Slaets D, Lambert B, Acou M, De Vos F, Goethals I: PET with 18F-labeled choline-based tracers for tumour imaging: a review of the literature. Eur J Nucl Med Molec Imaging 2010, 37:1188–2193.

2. Giovacchini G, Piccio M, Coradeschi E, Scattoni V, Bettinardi V, Cozzarini C, Freschi M, Fazio F, Messa C: 11CCholine uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy. Eur J Nucl Med Molec Imaging 2008, 35:1065–1073.

3. Reske S, Blumstein N, Glatting G: 11CCholine PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J Nucl Med Molec Imaging 2008, 35:9–17.

4. Fei BW, Wang HS, Wu CY, Chiu SM: Choline PET for monitoring early tumor response to photodynamic therapy. J Nucl Med 2010, 51:30–138.

5. Kause B, Soutizazoglou M, Herrmann K, Weber AW, Schuster T, Buck AK, Nawroth R, Weirich G, Treiber U, Wester HJ, Ziegler SJ, Seneckowitsch-Schmidtke R, Schweiger M: 11CCholine as pharmacodynamic marker for therapy response assessment in a prostate cancer xenograft model. Eur J Nucl Med Molec Imaging 2010, 37:1981–1988.

6. Boellaard R: Need for standardization of (18)F-FDG PET/CT for treatment response assessments. J Nucl Med 2010, 51:955–1005.

7. Tomasi G, Turkheimer F, Aboagye E: Importance of quantification for the analysis of PET data in oncology: review of current methods and trends for the future. Molec Imaging Biol 2012, 14:131–146.

8. Slaets D, De Bruyne S, Dumolyn C, Moerman L, Mertens K, De Vos F: Reduced dimethylaminooethanol in 11Cfluoromethylcholine: an important step towards enhanced tumour visualization. Eur J Nucl Med Molec Imaging 2010, 37:2136–2145.

9. Convert L, Martin-Brassard G, Cadorette J, Archambault M, Bentourkia M, Lecomte R: A new tool for molecular imaging: the microvolumetric beta counter. J Nucl Med 2007, 48:1197–1206.

10. Bansal A, Shuyan W, Hara T, Harris RA, Degrado TR: Biodisposition and metabolism of 11Cfluorocholine in 9L glioma cells and 9L glioma-bearing fisher rats. Eur J Nucl Molec Imaging 2008, 35:1192–1203.

11. Carson RE: Tracer kinetic modeling in PET. In Positron Emission Tomography: Basic Science and Clinical Practice. Volume 1. 1st edition. Edited by Valk PE, Bailey DL, Townsend DW, Maisey MN. London: Springer; 2003:147–179.

12. Patlak CS, Blasberg RG, Fenstermacher JD: Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Central Blood Flow and Metabolism 1983, 3:1–7.

13. Fujita M, Seibyl JP, Verhoeff NPLG, Ichise M, Baldwin RM, Zoghbi SS, Burger C, Staley JK, Rajeevan N, Charney DS, Innis RB: Kinetic and equilibrium analyses of 11Clepadipine binding to striatal and extrastriatal dopamine D2 receptors. Synapse 1999, 34:290–304.

14. Mankoff DA, Shields AF, Graham MM, Link JM, Eary JF, Krohn KA: Kinetic analysis of 2-11C thymidine PET imaging studies: compartmental model and mathematical analysis. J Nucl Med 1998, 39:1043–1055.

15. Muzi M, Mankoff DA, Grierson JR, Wells JM, Veselie H, Krohn KA: Kinetic modeling of 3-deoxy-3-fluorothymidine in somatic tumors: mathematical studies. J Nucl Med 2005, 46:371–380.

16. Patlak CS, Blasberg RG: Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow and Metab 1985, 5:584–590.

17. Feng D, Huang SC, Wang XM: Models for computer-simulation studies of input functions for tracer kinetic modeling with positron emission tomography. Int J Bio-Med Comp 1993, 32:95–110.

18. Burns KF, Delaney CW: Compendium of normal blood values of laboratory animals with indication of variations: I. Random-sexed populations of small animals. Toxicol and Appl Pharmacol 1996, 8:429.

19. Rovainen A, Forsback S, Gronroos T, Leikinonen P, Kähkönen M, Sutinen E, Heikki M: Blood metabolism of [methyl-11C]Choline: implications for in vivo imaging with positron emission tomography. Eur J Nucl Med Molec Imaging 2000, 27:25–32.